Heart Failure Management

Heart failure management is the long-term care of patients whose heart cannot pump or fill adequately to meet the body's needs, producing breathlessness, fatigue, and fluid retention. It is a progressive chronic syndrome managed across primary and specialist care, where the goals are to relieve symptoms, slow disease progression, and reduce hospitalisation and death.

Definition

Heart failure management is the longitudinal care of patients with the chronic clinical syndrome of heart failure — impaired cardiac pumping or filling causing congestion and reduced output — aimed at relieving symptoms, slowing progression, and reducing hospitalisation and mortality, within continuous, often multidisciplinary, care.

Scope

This entry describes the conceptual basis of managing chronic heart failure as a long-term condition: the distinction between reduced and preserved ejection fraction, the rationale for disease-modifying therapy, and the landmark trials and guidelines that define modern care. It is a reference orientation and does not provide individualised treatment or dosing guidance.

Core questions

• What distinguishes heart failure with reduced ejection fraction from that with preserved ejection fraction?
• Why is heart failure considered a progressive syndrome requiring disease-modifying therapy rather than only symptom relief?
• How did trials of newer agents change the goals and structure of heart-failure therapy?
• How is heart-failure care coordinated between primary care and specialist services?

Key concepts

• Heart failure with reduced ejection fraction (HFrEF)
• Heart failure with preserved ejection fraction (HFpEF)
• Ejection fraction
• Neurohormonal activation
• Disease-modifying (guideline-directed) therapy
• Decompensation and hospitalisation
• Self-monitoring and multidisciplinary care

Mechanisms

When cardiac output falls, compensatory neurohormonal systems (the sympathetic nervous system and the renin-angiotensin-aldosterone axis) activate; although initially adaptive, their sustained activation drives further myocardial injury, remodelling, and fluid retention, creating a self-perpetuating decline. Modern disease-modifying therapies act by blunting these maladaptive pathways, which is why they reduce progression and events rather than merely relieving symptoms. Newer agents, including SGLT2 inhibitors, were shown to reduce heart-failure events through mechanisms still being clarified.

Clinical relevance

Heart failure is a common cause of disabling symptoms and recurrent hospital admission, and much of its long-term, follow-up care occurs in primary care in coordination with specialists, making it a core chronic-disease topic. This entry explains how that management is conceived and supported by evidence; it is not a basis for individual diagnosis, drug selection, or dosing.

Epidemiology

Heart failure is a major and growing cause of morbidity, hospitalisation, and death, with prevalence rising as populations age and as survival from other cardiac disease improves. It commonly arises from coronary artery disease and hypertension and frequently co-occurs with diabetes and chronic kidney disease, situating it firmly within multimorbid chronic-disease care.

Evidence & guidelines

For heart failure with reduced ejection fraction, a series of trials defined disease-modifying therapy: PARADIGM-HF (McMurray and colleagues, 2014) established angiotensin-neprilysin inhibition over a comparator, and DAPA-HF (McMurray and colleagues, 2019) showed that an SGLT2 inhibitor reduced events. The 2021 ESC guidelines (McDonagh and colleagues) integrate these into a framework of guideline-directed medical therapy, while also addressing heart failure with preserved ejection fraction, for which effective therapies were historically more limited.

History

Heart failure was long treated chiefly by relieving congestion. Recognition that chronic neurohormonal activation drives progression reframed it as a syndrome amenable to disease modification, and successive randomised trials built a layered, guideline-directed therapy that improves survival in reduced ejection fraction. More recent trials extended benefit with newer drug classes, while heart failure with preserved ejection fraction remained a harder therapeutic target until later evidence began to emerge.

Debates

Treating heart failure with preserved ejection fraction

For decades, therapies that clearly improved outcomes in reduced ejection fraction failed to show the same benefit in preserved ejection fraction, leaving its optimal management uncertain and the subject of ongoing trials and debate.

Key figures

• John J. V. McMurray
• Theresa A. McDonagh
• Milton Packer

Seminal works

• mcmurray-2014
• mcmurray-2019
• mcdonagh-2021

Frequently asked questions

Does heart failure mean the heart has stopped working?

No. Heart failure means the heart cannot pump or fill efficiently enough to meet the body's needs, causing symptoms such as breathlessness and fluid retention; it is a chronic syndrome that is managed long term, not a cardiac arrest.

Why is heart-failure treatment described as 'disease-modifying'?

Several heart-failure therapies do more than relieve symptoms: by blunting the maladaptive neurohormonal responses that drive the syndrome, they slow progression and reduce hospitalisation and death, which is why they are central to long-term management of reduced ejection fraction.